Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Jets fall to Lightning for first road loss of season
Home secretary to announce extra £500m for neighbourhood policing
Bitcoin ETF options begin trading, ushering in a new way for investors to hedge their bitcoin exposure
Chinese vessel in area when Baltic Sea cables damaged
Kia debuts the 2026 EV9 GT for when your 7 friends need to get there real fast